Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a Phase 3 clinical study ...

Brittany Craiglow, MD, FAAD, analyzed the promising use of baricitinib for severe pediatric alopecia areata. She highlighted late-breaking data from the BRAVE-AA-PEDS study (NCT05723198 ...

1 Passeron T, et al. Baricitinib provides significant hair regrowth in adolescents with severe alopecia areata: 36-week efficacy and safety results from a Phase 3 randomized, controlled trial.

Patients share what they wish they had known before getting a diagnosis of alopecia areata, an autoimmune disease that causes hair loss.

HealthDay News — For adolescents with severe alopecia areata (AA), baricitinib is efficacious for hair regrowth, according to a study presented at the annual meeting of the American Academy of ...

ORLANDO, Fla. — Adolescents with severe or very severe alopecia areata (AA) were able to regrow hair, some with a 90% improvement in hair loss, after taking the Janus kinase inhibitor ...

WALTHAM, Mass., February 05, 2025--Thermo Fisher Scientific Inc. announced the launch of the international CorEvitas Adolescent Alopecia Areata (AA) Registry.

TOPLINE: Ritlecitinib demonstrates long-term improvements in regrowth of scalp hair, eyebrows, and eyelashes at 24 months in adults and adolescents with alopecia areata (AA) and ≥ 25% scalp hair ...

Late-breaking results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) found adolescent patients (ages 12 to under 18) with severe alopecia areata (AA) treated with once-daily ...

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study. Saturday, March 8, 2025 Research News. Advertisement ...